Dual renin-angiotensin-aldosterone system inhibition: boon or bust?

被引：0

作者：

Hirsch, S. ^{[1
]}

机构：

[1] Mercy Hosp, Chicago, IL 60602 USA

来源：

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2010年 / 64卷 / 10期

关键词：

CONVERTING ENZYME-INHIBITION; RANDOMIZED CONTROLLED-TRIAL; II RECEPTOR BLOCKER; KIDNEY-DISEASE; RENAL-DISEASE; DIABETIC-NEPHROPATHY; BLOOD-PRESSURE; DOUBLE-BLIND; PROTEINURIA; LOSARTAN;

D O I：

10.1111/j.1742-1241.2010.02367.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1337 / 1340

页数：4

共 21 条

[1] ONTARGET should not be over interpreted [J].

Abutaleb, Nasrulla .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (01) :44-47

[2]

[Anonymous], 2009, Lancet, V374, P1226, DOI 10.1016/S0140-6736(09)61768-2

[3] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[4] Supramaximal Dose of Candesartan in Proteinuric Renal Disease [J].

Burgess, Ellen ;

Muirhead, Norman ;

de Cotret, Paul Rene ;

Chiu, Anthony ;

Pichette, Vincent ;

Tobe, Sheldon .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (04) :893-900

[5] Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression [J].

Catapano, Fausta ;

Chiodini, Paolo ;

De Nicola, Luca ;

Minutolo, Roberto ;

Zamboli, Pasquale ;

Gallo, Ciro ;

Conte, Giuseppe .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 52 (03) :475-485

[6] Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker [J].

Chrysostomou, Anastasia ;

Pedagogos, Eugenia ;

MacGregor, Lachlan ;

Becker, Gavin J. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (02) :256-262

[7] Dual blockade of the renin-angiotensin system: The ultimate treatment for renal protection? [J].

Codreanu, I ;

Perico, N ;

Remuzzi, G .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 :S34-S38

[8] Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL [J].

de Zeeuw, D ;

Remuzzi, G ;

Parving, HH ;

Keane, WF ;

Zhang, ZX ;

Shahinfar, S ;

Snapinn, S ;

Cooper, MF ;

Mitch, WE ;

Brenner, BM .

KIDNEY INTERNATIONAL, 2004, 65 (06) :2309-2320

[9] Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A Randomized controlled study of benazepril and losartan in chronic renal insufficiency [J].

Hou, Fan Fan ;

Xie, Di ;

Zhang, Xun ;

Chen, Ping Yan ;

Zhang, Wei Ru ;

Liang, Min ;

Guo, Zhi Jian ;

Jiang, Jian Ping .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (06) :1889-1898

[10] Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis [J].

Jafar, TH ;

Stark, PC ;

Schmid, CH ;

Landa, M ;

Maschio, G ;

de Jong, PE ;

de Zeeuw, D ;

Shahinfar, S ;

Toto, R ;

Levey, AS .

ANNALS OF INTERNAL MEDICINE, 2003, 139 (04) :244-252

← 1 2 3 →